Progress in Neuro-Psychopharmacology

An International Research and Review Journal

Contents, Author Index and Subject Index

Volume 5

Pergamon Press

Oxford • New York • Frankfurt

Editor-in-Chief

C. Radouco-Thomas

Laval University Medical School
Quebec, Canada

Executive Editorial Board

T.A. BAN, *Nashville*
H. BARRY III, *Pittsburgh*
F.E. BLOOM, *San Diego*
D.P. BOBON, *Liège*
M.C. BRAUDE, *Rockville*
A. CARLSSON, *Göteborg*
C.L. CAZZULLO, *Milan*
M. CUENOD, *Zurich*
P. DENIKER, *Paris*
J. ELKES, *Baltimore*
D.X. FREEDMAN, *Chicago*
E. GERSHON, *Bethesda*
J. GLOWINSKI, *Paris*
H. HELMCHEN, *Berlin*
F. HOFFMEISTER, *Wuppertal*
L.E. HOLLISTER, *Palo Alto*
O. HORNYKIEWICZ, *Vienna*
A.G. KARCZMAR, *Chicago*
R.T. KELLEHER, *Boston*
P. KIEHOLZ, *Basle*
H. LAL, *Kingston, USA*
A.A. LEEDS, *Rockville*
H.E. LEHMANN, *Montreal*
G.M. LING, *Vienna*
J. MENDLEWICZ, *Brussels*
P. V. MOROZOV, *Geneva*
S. RADOUCO-THOMAS, *Quebec*
O.J. RAFAELSEN, *Copenhagen*
N. SARTORIUS, *Geneva*
S.H. SNYDER, *Baltimore*
H.M. VAN PRAAG, *Groningen*

Progress in Neuro-Psychopharmacology
An International Research and Review Journal

Editors-in-Chief

C. RADOUCO-THOMAS and F. GARCIN, *Laboratories of Neuro-Psychopharmacology, RADA Unit, Building D, Hospital Centre, St-Francois d'Assise, Quebec, Canada G1L 3L5*

General Executive Editor: D. BARONET-LACROIX, *Laboratories of Neuro-Psychopharmacology, RADA Unit, Building D, Hospital Centre, St-Francois d'Assise, Quebec, Canada G1L 3L5*

Executive Editorial Board

T. A. BAN
Vanderbilt University, Nashville
H. BARRY III
University of Pittsburgh, Pittsburgh
F. E. BLOOM
Salk Institute, San Diego
D. P. BOBON
Université de Liège
M. C. BRAUDE
National Institute on Drug Abuse, Rockville
A. CARLSSON
University of Göteborg, Göteborg
C. L. CAZZULLO
Milan
M. CUENOD
Brain Research Institute, Zurich
P. DENIKER
Höpital Ste-Anne, Paris
J. ELKES
Johns Hopkins University, Baltimore
D. X. FREEDMAN
University of Chicago, Chicago
E. GERSHON
Bethesda, Maryland
J. GLOWINSKI
Collège de France, Paris
H. HELMCHEN
Freie Universität, Berlin
F. HOFFMEISTER
Institute of Pharmacology, Bayer AG, Wuppertal
L. E. HOLLISTER
Veterans Administration Hospital, Palo Alto
O. HORNYKIEWICZ
Institute of Biochemical Pharmacology, Vienna
A. G. KARCZMAR
Loyola University, Chicago
R. T. KELLEHER
Harvard Medical School, Boston
P. KIELHOLZ
University of Basle, Basle
H. LAL
Kingston, USA
A. A. LEEDS
National Institute of Mental Health, Rockville
H. E. LEHMANN
McGill University, Montreal
G. M. LING
United Nations, Narcotic Division, Vienna
J. MENDLEWICZ
Brussels
P. V. MOROZOV
Geneva, Switzerland
S. RADOUCO-THOMAS
Laval University Medical School, Quebec
O. J. RAFAELSEN
Psychochemistry Institute, Copenhagen
N. SARTORIUS
Geneva, Switzerland
S. H. SNYDER
Johns Hopkins University, Baltimore
H. M. VAN PRAAG
Psychiatric University Clinic, Groningen

Aims and Scope

This new journal provides an international and interdisciplinary medium for the rapid publication of authoritative research papers and review articles dealing with experimental, clinical and social aspects of neuro-psychopharmacology.
The original contributions to be published will deal mainly with the mechanism and site of action of neuro-psychotropic drugs at the various levels of organization of the brain. Experimental papers reporting joint studies at the molecular, cellular and behavioural level are strongly encouraged. Particular attention will be paid to the clinical and socio-medical investigations having close relationship with the basic mechanism of action of neuro-psychotropic drugs. One of the main aims of the journal is to improve exchanges and to assure better communication between members of the neuro-psychopharmacological community. For this purpose, a part of the journal will be devoted to disseminating information in the field of research, teaching and other professional activities. The Editors and Publishers will also try to do their best to encourage and promote exchanges in these various fields in developing countries.

Publishing, Subscription and Advertising Offices: Pergamon Press Ltd., Headington Hill Hall, Oxford OX3 0BW. (Oxford 64881; Telex 83177).
Address for subscription enquiries in North America: Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523, U.S.A.
Published bi-monthly. Annual subscription 1982 (including postage and insurance): for Libraries, Research Establishments and all other multiple-reader institutions — U.S. $135.00. Two years 1982/83 — $256.50.

Specially Reduced Rates to Individuals: In the interest of maximizing the dissemination of the research results published in this important journal we have established a two-tier price structure. Any individual whose institution takes out a library subscription may purchase a second or additional subscription for personal use at a much reduced rate of U.S. $45.00 per annum.

Microform Subscriptions and Back Issues: Back issues of all previously published volumes will be available in the regular editions and on microfilm and microfiche. Current subscriptions are available on microfiche simultaneously with the paper edition and on microfilm on completion of the annual index at the end of the subscription year.

Copyright © 1982 Pergamon Press Ltd.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organizations which do not permit such assignment. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise without permission in writing from the copyright holder.

U.S. Copyright Law applicable to Users in the U.S.A.

The Article Fee code on the first page of an article in this journal indicates the copyright owner's consent that in the U.S.A. copies may be made for personal or internal use provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance should be forwarded with a copy of the first page of the article to the Copyright Clearance Center Inc., 21 Congress Street, Salem, MA 01970. If a code does not appear copies of the article may be made without charge, provided permission is obtained from the publisher. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works or for resale. Specific written permission must be obtained from the publisher for such copying.
In case of doubt please contact your nearest Pergamon office.

PERGAMON PRESS

HEADINGTON HILL HALL
OXFORD OX3 0BW, ENGLAND

MAXWELL HOUSE, FAIRVIEW PARK
ELMSFORD, NEW YORK 10523, USA

CONTENTS

Volume 5. No. 1

Editorial advisory board

Organization of the journal

Critical reviews and theoretical articles

W. R. Klemm — 1 — Opiate mechanisms: Evaluation of research involving neuronal action potentials

Full-length original papers

Experimental laboratory studies

A. G. Karczmar and G. H. Kindel — 35 — Acetylcholine turnover and aggression in related three strains of mice

R. J. Katz — 49 — Possible muscarinic-cholinergic mediation of patterned aggressive reflexes in the cat

G. T. Shearman and H. Lal — 57 — Discriminative stimulus properties of cocaine related to an anxiogenic action

Clinical studies

B. E. Golinko, P. M. Rennick and R. F. Lewis — 65 — Predicting stimulant effectiveness in hyperactive children with a repeatable neuropsychological battery: A preliminary study

A. Dotti, O. Lostia, I. A. Rubino, G. Bersani, L. Carilli and D. Zorretta — 69 — The prolactin response in patients receiving neuroleptic therapy. The effect of fluphenazine decanoate

J. Tegeler and E. Lehmann — 79 — A follow-up study of schizophrenic outpatients treated with depot-neuroleptics

M. Gastpar and W. Muller — 91 — Auto-antibodies in affective disorders

G. B. Cassano, C. Maggini and M. Guazzelli — 99 — Nocturnal angina and sleep

News and intercommunications in neuropsychopharmacology — 105 — 1: In memoriam; 2: Reports on past meetings; 3: Comments on forthcoming meetings; 4: Employment opportunities

i — Instructions to contributors

v — Editorial policy

vi — Forthcoming paper

CONTENTS

Volume 5. No. 2

Editorial advisory board

Organization of the journal

Full-length original papers

Experimental laboratory studies

T. Nabeshima, K. Fujimori and I. K. Ho — 121 Effect of acute or chronic pentobarbital administration on the steady state levels and the turnover rates of catecholamines in discrete brain areas of mice

Clinical studies

G. B. Cassano *et al.* — 129 A multicenter controlled trial in phobic-obsessive psychoneurosis. The effect of chlorimipramine and of its combinations with haloperidol and diazepam

Special Topic:

Symposium on "Anxiety-Fear-Phobia"

Topic Editors: M. Lader and W. P. Koella

W. P. Koella — 139 Introduction

M. Lader — 141 Introduction

J. A. Gray, N. Davis, J. Feldon, J. Nicholas, P. Rawlins and S. R. Owen — 143 Animal models of anxiety

S. Garattini and L. Valzelli — 159 Is the isolated animal a possible model for phobia and anxiety?

H. Heimann and H. Giedke — 167 Psychophysiology of anxiety, fear and phobia

I. M. Marks — 179 Anxiety states, phobic and obsessive-compulsive disorders. Clinical picture, differential diagnostic and management

W. P. Koella — 187 Electroencephalographic signs of anxiety

M. Lader — 193 Synthesis and conclusion

Special Topic:

Communications in Neuro-Psychopharmacology

Topic Editor: Alice Leeds

H. Feer — 197 Communication from the viewpoint of the european regional reference center

F. E. Vartanian — 201 The role of information exchange in psychopharmacology

P. Kielholz — 205 Comments on the foundation and activities of the international committee for prevention and treatment of depression

News and intercommunications in neuro-psychopharmacology — 211 1: Past and forthcoming meetings; 2: Employment opportunities

i Instructions to authors

v Editorial policy

vi Announcement and forthcoming papers

CONTENTS

Volume 5. No. 3

Editorial advisory board

Organization of the journal

Critical reviews and theoretical articles

M. D. Morris and G. F. Gebhart — 219 Antianxiety agents and emotional behavior: An information processing analysis

Full-length original papers

Experimental laboratory studies

L. A. Grupp — 241 Ethanol as the negative reinforcer in an active avoidance paradigm

S. E. File — 245 Effects of a piperazine derivative, piribedil, on exploration locomotor activity and social behavior in the rat

Clinical studies

J. Ananth, J. C. Pecknold, N. van den Steen and F. Engelsmann — 257 Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis

W. H. Wilson, W. M. Petrie, T. A. Ban and D. E. Barry — 263 The effects of amoxapine and ethanol on psychomotor skills related to driving: A placebo and standard controlled study

Short and preliminary papers

M. D. Hynes and H. Lal — 271 Chronic haloperidol treatment fails to alter the anorexic actions of dopaminergic agonists and cholinergic drugs

S. E. Møller and L. Kirk — 277 Decreased tryptophan availability in endogenous depression caused by disturbed plasma leucine clearance

Editorial note

K. Ornstein — 281 Stress induced facilitation of opiate catalepsy in the rat: A reply to R. J. Katz

Special contributions — 283 Abstracts presented at the fourth annual meeting of the Canadian College of Neuro-Psychopharmacology, Toronto, April 23–25, 1981

News and intercommunications in neuropsychopharmacology — 327 1: Past and forthcoming meetings; 2: Employment opportunities

i Instructions to contributors

v Editorial policy

CONTENTS

Volume 5. No. 4

Editorial advisory board

Organization of the journal

Critical reviews and theoretical articles

W. M. Petrie and T. A. Ban — 335 Psychopharmacology for the elderly

M. E. Zarranz de Ysern and L. A. Ordoñez — 343 Tetrahydroisoquinolines: A review

Full-length original papers

Experimental laboratory studies

H. Frances, M-H. Marion and P. Simon — 357 Antidepressant action of lithium: Proposed mechanism based upon behavioral analysis in the mouse

R. Numan and H. Lal — 363 Effect of morphine on rectal temperature after acute and chronic treatment in the rat

T. Nabeshima and I. K. Ho — 373 Acute and chronic effects of pentobarbital on 5-hydroxytryptamine in mouse brain

S. L. Cohen, B. J. Morley and O. Carter Snead — 383 An EEG analysis of convulsive activity produced by cholinergic agents

Clinical studies

L. Evans and J. Cox — 389 A comparative study of the therapeutic effect and cardiotoxicity of dothiepin HC1 and doxepin HC1 in reactive depression

M. M. Ghoneim, S. P. Mewaldt and R. C. Petersen — 395 Subanesthetic concentration of nitrous oxide and human memory

K. R. Lagergren — 403 Sub-optimal vigilance in patients with complete heart block: Influence of cardiac pacing and a "nootropic" substance

Short original papers

C. T. Dourish and A. A. Boulton — 411 The effects of acute and chronic administration of β-phenylethylamine on food intake and body weight in rats

T. Suzuki, T. Yoshii, S. Yanaura, R. Fukumori, T. Satoh and H. Kitagawa — 415 Effect of parachlorophenylalanine on the incidence of abnormal behaviors observed following diazepam withdrawal

News and intercommunications in neuro-psychopharmacology — 421 1: Past and forthcoming meetings; 2: Employment opportunities

i Instructions to contributors

v Editorial policy

vi Forthcoming special contributions

CONTENTS

Volume 5. No. 5/6

Editorial advisory board

Organization of the journal

Mini-reviews

C. A. Naranjo, L. Fornazzari and E. M. Sellers — 427 Clinical detection and assessment of drug induced neurotoxicity

E. G. McGeer — 435 Neurotransmitter systems in aging and senile dementia

M. Fisman — 447 Clinical pharmacology of senile dementia

J. M. Khanna, H. Kalent, A. D. Lê and A. E. LeBlanc — 459 Role of serotonergic and adrenergic systems in alcohol tolerance

R. A. Wise and M. A. Bozarth — 467 Brain substrates for reinforcement and drug self-administration

M. B. Sobell — 475 The nature of alcohol problems: Old concepts and new

Original papers

Pharmacotherapy

G. Chouinard, L. Annable and R. Langlois — 483 Absence of orthostatic hypotension in depressed patients treated with bupropion

D. Radonjic, Y. D. Lapierre and V. Knott — 491 The effect of methylphenidate on tardive dyskinesia

J. Simeon, J. Magiure and S. Lawrence — 495 Maprotiline effects in children with enuresis and behavioural disorders

R. P. De Buck, N. Zelaschi, C. Gilles, J. Durdu and H. Brauman — 499 Theoretical and practical importance of plasma levels of haloperidol. Correlations with clinical and computerized EEG data

E. S. Werstiuk, M. P. Rathbone and P. Grof — 503 Phloretin-sensitive lithium transport in erythrocytes of affectively ill patients: Intra-individual reproducibility

D. Sarantidis and B. Waters — 507 Predictors of lithium prophylaxis effectiveness

V. Knott, R. Chaudhry and Y. D. Lapierre — 511 Panic induced by sodium lactate: Electrophysiological correlates

J. M. Baker, S. L. Handley, G. Waldron and T. L. Dunn — 515 Seasonal variation in plasma tryptophan in parturient women

D. P. Bobon, Y. D. Lapierre and T. Lottin — 519 Validity and sensitivity of the French version of the Zerssen BfS/BfS' self-rating mood scale during treatment with trazodone and amitriptyline

Neurotransmitters and receptors

L. J. Grota, V. Snieckus, S. Osmond De Silva, H. W. Tsui, W. R. Holloway, A. J. Lewy and G. M. Brown — 523 Radioimmunoassy of melatonin in rat serum

P. Ahluwalia, D. S. Grewaal and R. L. Singhal — 527 Brain gabaergic and dopaminergic systems following lithium treatment and withdrawal

P. P. Li, J. J. Warsh and D. D. Godse — 531 3, 4 dihydroxyphenylethyleneglycol (DHPG) formation: The major route of rat brain norepinephrine metabolism

CONTENTS

Volume 5. No. 5/6, *continued*

W. McIntyre Burnham, G. A. King and K. G. Lloyd	537	Extra-focal catecholamine levels in 'kindled' rat forebrains
B. K. Madras, A. Davis, B. Chan and P. Seeman	543	Solubilized dopamine/neuroleptic receptors D_2-type
N. Kato, K. R. Shah, H. G. Friesen and V. Havlicek	549	Effect of chronic treatment with haloperidol on serum prolactin, striatal opiate receptors and β-endorphin content in rat brain and pituitary
P. D. Hrdina	553	Pharmacological characterization of [^{3}H] desipramine binding in rat cerebral cortex
A. S. Chiu, D. D. Godse and J. J. Warsh	559	Determination of brain regional normetanephrine levels by liquid chromatography with electrochemical detection (LC – EC)
R. T. Coutts, G. B. Baker, D. F. LeGatt, G. J. McIntosh, G. Hopkinson and W. G. Dewhurst	565	Screening for amines of psychiatric interest in urine using gas chromatography with electron-capture detection
D. J. Edwards and M. Rizk	569	Effects of amino acid precursors on catecholamine synthesis in the brain
O. M. Pulido, G. M. Brown and L. J. Grota	573	Localization of N-acetylserotonin (NAS) in the rat hindbrain by immunohistology
G. B. Baker and D. L. Yasensky	577	Interactions of trace amines with dopamine in rat striatum
G. D. Prell and I. M. Mazurkiewicz-Kwilecki	581	The effects of ethanol, acetaldehyde, morphine and naloxone on histamine methyltransferase activity
Animal models		
J. I. Telner, R. L. Singhal and Y. D. Lapierre	587	Reversal of learned helplessness by nortriptyline
J. N. Nestoros	591	Anxiety as a state of diminished gabaergic neurotransmission resulting from too frequent recruitment of gabaergic neurons: A neurophysiological model
A. Barta and K. Yashpal	595	Regional redistribution of β-endorphin in the rat brain: The effect of stress
P. Zvolsky, L. Jansky, J. Vyskocilova and P. Grof	599	Effects of psychotropic drugs on hamster hibernation — Pilot study
Z. Merali	603	Prolactin levels and amphetamine-induced behavioural changes following fluphenazine decanoate administration
R. B. Stewart and L. A. Grupp	609	An investigation of the interaction between the reinforcing properties of food and ethanol using the place preference paradigm
C. Szostak, T. N. Tombaugh and J. Tombaugh	615	Examination of the effects of pimozide on two conditional discrimination problems differing in levels of task complexity
F. Garcin, D. Kasiencsuk, S. Radouco-Thomas, J. Cote and C. Radouco-Thomas	619	NAD+ – dependent acetaldehyde oxidation in drosophila
News and intercommunications in neuro-psychopharmacology	629	Special announcement
	i	Instructions to contributors
	v	Editorial policy

AUTHOR INDEX

Ahluwalia, P. 527
Amabile, G. 129
Ananth, J. 257
Annable, L. 483

Baker, G. B. 565, 577
Baker, J. M. 515
Balestrieri, A. 129
Ban, T. A. 263, 335
Barry, D. E. 263
Barta, A. 595
Bedarida, D. 129
Benecchi, M. V. 129
Bersani, G. 69
Bobon, D. P. 519
Boulton, A. A. 411
Bozarth, 467
Brauman, H. 499
Brown, G. M. 523, 573
Burti, L. 129

Carilli, L. 69
Carter Snead, O. 383
Cassano, G. B. 99, 129
Castrogiovanni, P. 129
Catalano, A. 129
Cerone, G. 129
Chan, B. 543
Chaudhry, R. 511
Chouinard, G. 483
Chiu, A. S. 559
Cohen, S. L. 383
Cote, J. 619
Coutts, R. T. 565
Cox, J. 389

Davis, A. 543
Davis, N. 143
De Buck, R. P. 499
Dewhurst, W. G. 565
Dotti, A. 69
Dourish, C. T. 411
Dunn, T. L. 515
Durdu, J. 499

Edwards, D. J. 569
Engelsmann, F. 257
Evans, L. 389

Feer, H. 197
Feldon, J. 143
Frances, H. 357
Friessen, H. G. 549
File, S. E. 245
Fisman, M. 447
Fornazzari, L. 427
Fujimori, K. 121
Fukumori, R. 415

Garattini, S. 159
Garcin, F. 619
Gastpar, M. 91
Gebhart, G. F. 219
Ghoneim, M. M. 395
Giedke, H. 167
Gilles, C. 499
Godse, D. D. 531, 559
Golinko, B. E. 65
Gray, J. A. 143
Grewaal, D. S. 527
Grof, P. 503, 599
Grota, L. J. 523, 573
Grupp, L. A. 241, 609
Guazzelli, M. 99
Guidotti, N. 129

Handley, S. L. 515
Havlicek, V. 549
Heimann, H. 167
Holloway, W. R. 523
Ho, I. K. 121, 373
Hopkinson, G. 565
Hrdina, P. D. 553
Hynes, M. D. 271

Jansky, L. 599

Kalent, H. 459
Karczmar, A. G. 35
Kasiencsuk, D. 619
Kato, N. 549
Katz, R. J. 49
Khanna, J. M. 459
Kielholz, P. 205
Kindel, G. H. 35
King, G. A. 537
Kirk, L. 277
Kitagawa, H. 415
Klemm, W. R. 1

Knott V. 491, 511
Koella, W. P. 139, 187

Lader, M. 141, 193
Lagergren, K. R. 403
Lal, H. 57, 271, 363
Langlois, R. 483
Lapierre, Y. D. 491, 511, 519, 587
Lawrence, S. 495
Lê, A. D. 459
LeBlanc, A. E. 459
Legatt, D. F. 565
Lehmann, E. 79
Lewis, R. F. 65
Lewy, A. J. 523
Li, P. P. 531
Lloyd K. G. 537
Lostia, O. 69
Lottin, T. 519

Madras, B. K. 543
Maggini, C. 99
Magiure, J. 495
Marchetti, F. P. 129
Marks, I. M. 179
Marion, M-H. 357
Mauri, M. 129
Mazurkiewicz-Kwilecki, I. M. 581
McGeer, E. G. 435
McIntosh, G. J. 565
McIntyre Burnham, W. 537
Merali, Z. 603
Mewaldt, S. P. 395
Møller, S. E. 277
Morley, B. J. 383
Morris, M. D. 219
Muller, W. 91

Nabeshima, T. 121, 373
Naranjo, C. A. 427
Nestoros, J. N. 591
Nicholas, J. 143
Nielsen, N. P. 129
Numan, R. 363

Ordoñez, L. A. 343
Ornstein, K. 281
Osmond de Silva, S. 523
Owen, S. R. 143

Pariante, F. 129
Pecknold, J. C. 257
Petersen, R. C. 395
Petrie, W. M. 263, 335
Pirro, R. 129
Prell, G. D. 581
Pugliese, L. 129
Pulido, O. M. 573

Radonjic, D. 491
Radouco-Thomas, C. 619
Radouco-Thomas, S. 619
Rathbone, M. P. 503
Rawlins, P. 143
Reitano, S. 129
Rennick, P. M. 65
Rizk, M. 569
Rocco, M. L. 129
Rubino, I. A. 69
Rutigliano, G. 129

Sarantidis, D 507
Satoh, T. 415
Seeman, P. 543
Sellers, E. M. 427
Shah, K. R. 549
Shearman, G. T. 57
Simeon, J. 495
Simon, P. 357
Singhal, R. L. 527, 587
Snieckus, V. 523
Sobell, M. B. 475
Stewart, R. B. 609
Suzuki, T. 415
Szostak, C. 615

Tansella, M. 129
Tegeler, J. 79
Telner, J. I. 587
Tombaugh, J. 615
Tombaugh, T. N. 615
Tsui, H. W. 523

Valzelli, L. 159
Van Den Steen, N. 257
Vartanian, F. E. 201
Vyskocilova, J. 599

Waldron, G. 515
Warsh, J. J. 531, 559
Waters, B. 507
Werstiuk, E. S. 503
Wilson, W. H. 263
Wise, R. A. 467

Yanaura, S. 415
Yasensky, D. L. 577
Yashpal, K. 595
Yoshii, T. 415

Zanasi, M. 129
Zarranz De Ysern, M. E. 343
Zelaschi, N. 499
Zorretta, D. 69
Zvolsky, P. 599

SUBJECT INDEX

Acetaldehyde
  and histamine methyltransferase 581–5
  NAD dependent oxidation in *Drosophila* sp 619–27
  oxidation time course 621–3
Acetylcholine
  and aggression in mice 35–46
  endogenous levels and stress 38–44
N-Acetylserotonin
  immunohistological localization 573–5
  regulation in cerebellum 309
Adrenalectomy, temperature effects in morphine tolerance 366–9
Adverse drug reactions
  classifications 428
  clinical signs 430–4
  consciousness 430
  cranial nerves 432
  dyskinesias 432, 433
  headache 431, 432
  information sources 429, 430
  myopathies 433
  neuropathies 433
Affective disorders and autoantibodies 91–6
Aging, neurotransmitter systems 435–42
Aggression
  and acetylcholine turnover in mice 35–46
  antianxiety drugs 226
  arecoline 51–4
  drug effects in mice 162, 163
  paradigm 38
  production in animals 223
  reflexes and muscarinic, cholinergic mediation 49–56
  scopolamine 54, 55
Agoraphobia 181, 182
  diazepam 184
Alcoholics Anomymous 476
Alcoholism
  affective disorders 306, 307
  drinking, reasons for 178, 179
  familial 310
  problems 324, 475–80
Alcohol tolerance
  adrenergic systems 459–64
  serotonergic and adrenergic system 322
  serotonergic systems 459–64
Alzheimer's disease 436
  brain noradrenergic system 294
  lecithin effects 305, 306
Amines, psychiatric interest 293, 565–8
Amino acid precursors and catecholamine synthesis 569–72
Amitriptyline
  blood pressure and pulse 487
  depth perception 268
  hypotension 485
  motor reflex 266
  obsessive neurosis study 257–62
  self-rating mood scale 519–22
  side effects 260, 261
  visual motor coordination 267
Amoxapine
  depth perception 268
  driving skills 263–70
  motor reflex 266
  visual motor coordination 267
Amphetamine and eating behaviour with haloperidol 272, 273
Angina
  nocturnal and sleep 99–104
  treatment of insomnia 101, 102
Animal models
  anxiety 143–56, 159–63
  isolated 159–63
Antianxiety drugs 143, 219–36
  and aggression 226, 227
  fear 223–5, 227
  frustration 225–7
  response inhibition 232, 234
  response selection 232–4
  stimulus selection 231–3
Anxiety
  animal models 143–56, 159–63, 220–3
  clinical diagnosis 180, 181
  CNS structures 190
  counter-conditioning model 154
  definition 179
  diminished GABAergic neurotransmission 591–5
  EEG signs 187–91
  need for classification 193
  neural substrate 144, 145
  neurophysiological model 306
  neurophysiology 194
  overarousal 194
  psychology 143, 144
  psychophysiology 167–76
  running speed in alley 149
  skin conductance 171–3
  symptoms 187
Apomorphine
  and eating behaviour with haloperidol 272, 273
  stereotypy 314, 315
Arecoline 50
  biting 52, 53
  pawing 52, 53

Autoantibodies
affective disorders 91–6
antinuclear factor 91
basement membrane 91
mitochondria 91
rheumatoid factor 91
thyroglobulin 91
Automatic diagnostic procedure 137
Aversive stimuli 241–4

Barbiturates and GABA 592
Behaviour
amphetamine induced and fluphenazine 603–7
appetitively reinforced 230
eating and drugs 272, 273
emotional and anxiety drugs 219–36
exploratory 248–51
feeding and phenylethylamine 411–14
head-dipping 249–51
locomotor 248–51
social and piperazines 245–54
Behavioural analysis and lithium 357–61
Behavioural inhibition, anxiety model 145
Behaviour tests
aggression 36, 37
arecoline 51–4
Benzodiazepines and aggression in mice 162, 163
Biogenic aldehydes 347
Brain
aging mechanisms 320, 321, 323
desipramine binding 553–7
kindled, catecholamine levels 290, 537–40
reinforcement substrates 324, 325, 467–72
Brain regions
pentobarbital and catecholamines 124, 125
relationships 147
saggital section 148
Brief psychiatric rating scale 499, 501
expanded 131
Bupropion
blood pressure and pulse 487
and hypotension in depression 291, 292, 483–9
plasma levels 488
side effects 487

Catecholamines
aging 437, 438
analysis methods 303
kindled brains 538, 539
mouse brain and pentobarbital 121–7
synthesis and amino acid precursors 295, 569–72
Chlordiazepoxide
anxiety in rats 149, 150
and norepinephrine depletion 288
Chlorimipramine
multicenter trial in phobic-obsessive psychoneurosis 129–38
side effects 135
p-Chlorophenylalanine, 5-HT depletion 379
Choline
acetyltransferase 440
and aging 439, 440
endogenous levels and stress 38–44
Cholinergic agents
convulsive activity 383–7
list 385
Cholinergic system
aging 438
aggression in cat 49–56
drugs and eating behaviour 272, 273
Clomipramine
obsessive neurosis study 257–62
side effects 260, 261
structural formula 257
Cocaine and discriminative stimuli 57–61
Codeine analgesia 313
Cognitive-perceptual-motor battery 66, 67
Conditional discrimination
pimozide and task complexity 615–18
Conditioned acceleration procedure 224
Conditioned emotional response 221
Critical flicker fusion frequency test 404

Depression *see also* International Committee
autoantibodies 91–6
biochemical differentiation 317, 318
bulletin 207
elderly and monoamine oxidase inhibition 290
incidence 206
leucine clearance 277–9
psychophysiology 167–76
reactive and drugs 389–92
tryptophan availability 277–9
Desipramine, brain binding 298, 299, 553–6
Dextroamphetamine and hyperactivity 65–7
Diazepam
and discriminative stimuli 57–61
phobias 184
psycho-obsessive neuroses 129–38
side-effects 135
withdrawal and parachlorophenylalanine 415–17
3, 4-Dihydrophenylacetic acid and catecholamine levels 537–40
3, 4-Dihydrophenylethylene glycol 302, 303
and norepinephrine metabolism 531–4
Dihydroxyphenylserine and brain catecholamine synthesis 570, 571
Discrimination training and testing 58
L-Dopa and brain catecholamines 570
Dopamine
and lithium 538
nigro-striatal 289
pentobarbital in mouse brain 123, 126
prolactin regulation 296
trace amine interaction 286, 287, 577–80
Dopaminergic system and lithium 527–30
Dothiepin therapy and cardiotoxicity 389–92
Doxepin therapy and cardiotoxicity 389–92
Driving, ethanol and amoxapine effects 263–70

Drosophila melanogaster
alcochol disposition pathways 619–26
Drugs
beta-blocking and aggression in mice 162, 201–3
carry over 264
elderly 335–9
isolated aggressive mice 161
neurotoxicity detection 427–34
psychotropic and hibernation 319, 599–602
psychotropic, information and numbers 197–201, 201–3
rat cortex affinity 556
rewards 469–71
self-administration, brain substrates 467–72
vasodilator and senile dementia 447, 448

Elderly
antidepressants 336, 337
antipsychotics 337
cerebral metabolism 337
neuropeptides 338
psychopharmacology 335–9
Electroencephalography (EEG)
anxiety 187–91
cholinergic convulsive activity 383–7
contingent negative variation 188–90
general features 188
Endorphins 5, 6
distribution in rat brain and stress 287, 288, 595–8
and haloperidol 549–52
Eneuresis, maprotiline effects 312, 495–8
Enkephalins 5, 6
Erythrocytes, lithium efflux 503–6
ET495 see piribedil 245
Ethanol
choice reaction time 266, 267
depth perception 268
driving skills 263–70
disposal pathways 619–26
food reinforcement interaction 609–13
GABA 592
histamine methyltransferase 581–5
negative reinforcement in acute avoidance 241–4
visual motor coordination 267
withdrawal syndrome treatment 309, 310
European Regional Reference Center 197–200

Factor analysis, interrater reliability 317, 321
Fear
antianxiety drugs 223–5
definition 180
production in animals 220
psychophysiology 167–70
Flupenthixole and schizophrenia follow-up 88
Fluphenazine
plasma prolactin 606
prolactin and behaviour effects 304, 305
prolactin response to neuroleptics 69–76
and schizophrenia follow-up 88
Flurazepam, pharmacokinetics 293
Fluspirilen and schizophrenia follow-up 88
Frustration
antianxiety drugs 225, 226
production in animals 222, 223

GABA systems
aging 438
lithium 527–30
GABAergic neurotransmission in anxiety 591–4
Gas chromatography and electron capture
amines 293, 565–8
Glycine, CNS and sodium independent binding 299, 300
Growth hormone, apomorphine response in schizophrenia 292

Haloperidol
assay and clinical data 294
chronic and anorexia 271–4
chronic and prolactin 549–52
chronic treatment effects 299
discriminative action 57–61
dopaminergic–cholinergic drugs 271–4
phobic-obsessive psychoneuroses 129–38
plasma level in schizophrenia 311, 499–502
side effects 135
Hamilton's Rating Scale for Depression 131
dothiepin and doxepin 390, 391
skin conductance 172, 173
Heart block, mental performance 403–8
Helplessness, nortriptyline reversal 587–90
Hibernation, psychoactive drugs 319, 599–602
Hippocampectomy 154
Hippocampus
antianxiety drug action 153
organization 146
-septal relationship 147, 148
Histamine methyltransferases, drug effects 308, 309, 581–5
5-Hydroxytryptamine, pentobarbital effects on brain 373–80
Hyperactive children, prediction of stimulus effectiveness 65–7
Hyperkinesis, spinal motoneuronal activity 308
Hypotension, orthostatic
in bupropion treated depression 291, 292, 483–9

Imipramine
brain binding 298, 299, 553–7
hibernation 601
Immunohistology, *N*-acetylserotonin localization 573–6
Indalpine, rating scales 317
Information 197–200, 201–3
Inpatient Multidimensional Psychiatric Scale 131

International Committee for Prophylaxis and Therapy of Depression 199, 200
  foundation and activities 205–8
  network in Europe 206
International Reference Center for Psychiatric Drugs 199
Isolation syndrome 159, 160

Jellinek's disease concept 476, 477

Krakau's Visual Acuity Test 404

La Tourette syndrome, prolactin and pimozide 305
Lecithin 305, 306
Leucine clearance in depression 277–9
Liquid chromatography and electrochemical detection (LC–EC) 291, 559–62
  brain stem amines 560–2
Lithium
  antidepressant action 357–61
  dopaminergic systems 527–30
  drug interactions 359, 360
  GABAergic systems 527–30
  hypothermia 360
  phloretin sensitive transport 318, 319, 503–6
  prophylaxis effectiveness 507–10
  treatment and withdrawal effects 286
  water intake 359
Lithium carbonate treatment and outcome 311, 312
Lithium chloride and hibernation 601
Locomotor activity, factors affecting 307

Mania-depression 300, 301, 322, 323
  and lithium 507–10
Maprotiline, functional enuresis 312, 495–8
Melatonin, radioimmunoassay 297, 298, 523–6
Memory and subanaesthetic nitrous oxide 395–401
Methylphenidate and tardive dyskinesia 309, 491–4
alpha-Methyl-*p*-tyrosine and mouse brain catecholamines 125, 126
Mice, acetylcholine and aggression 35–46
Minnesota Multiphasic Personality Inventory 131
  phobic-obsessiveness 132, 133
Mirror-image study
  depot neuroleptics 79–89
  patient characteristics 80, 81
Models
  counter-conditioning 154
  GABAergic 591–4
  information processing, antianxiety drugs 226–35
Mood, Zerssen self-assessment 288, 289, 320, 519–22
Morphine
  and histamine methyltransferase 581–5
  neutrotransmission 17
  rat rectal temperature 363–70
Multiple Trial Free Recall Test 399
Muscarinic system and aggression in cat 49–56

Naloxone and histamine methyltransferase 581–5
Naltrexone and morphine-induced temperature change 366
Negative reinforcement, ethanol 241–4
Neuroleptics
  depot, assessment in schizophrenia 79–89
  long-acting 83, 84
  short-acting 82
Neurotoxicity *see also* adverse drug reactions
  assessment of drug-induced 427–34
  drug-induced, clinical diagnosis 323
  epidemiological assessment 321
Neurotransmitters in aging and senile dementia 435–43
Nitrous oxide
  memory 395–401
  objective response 398
Nomifensine, self-administration 313, 314
Noradrenaline and feeding behaviour 317
Norepinephrine
  alcohol tolerance 462
  depletion and conflict 288
  glycol metabolites 297
  metabolism and 3, 4-dihydroxyphenylethylene-glycol 531–4
  and pentobarbital in mouse brain 123
Normetanephrine, detection methods 291, 559–62
Nortriptyline, learned helplessness 316, 587–90

Obsessive neurosis
  clonipramine 257
  questionnaire 259
Obsessive-compulsive disorders 182, 183
  and depression 183
Opiates
  and amygdala 23
  antinociception 24
  brain stem reticular function 26, 27
  catalepsy and stress 281
  central grey 28
  cholinergic function 18, 19
  depressive effects 8, 9
  dopaminergic systems 20, 21
  excitation mechanisms 12
  excitatory effects 9–11
  hippocampus 22, 23
  limbic system 22
  locomotor function 21, 22
  mechanisms 1–29
  molecular action 4, 5
  neurotransmission 16–21
  nonspecific excitation 15, 16
  noradrenergic function 19, 20
  raphe 28
  regional differences of effects 6–8
  spinal analgesia 24–6
  thalamus 29
  tolerance 13–16

Opioids, endogenous and exogenous 2–29

Pacemakers and mental performance 403–8
Pain, chest and sleep 99, 100
Panic, sodium lactate induced 300, 511–14
Parachlorophenylalanine
  diazepam withdrawal behaviour 415–17
Pargyline and pentobarbital brain effects 377
Partial punishment effect 145
Partial reinforcement extinction 145
Parturient women, seasonal variation in tryptophan 287, 515–18
Penfluridol and schizophrenia follow-up 88
Pentobarbital
  catecholamine turnover in mice brain 121–7
  and 5-HT accumulation 378
  and 5-HT in rat brain 373–81
Pentylenetetrazol, anxiolytic and discriminative action 57–61
Pharmacogenetics, *Drosophila* sp 296, 297
beta-Phenylethylamine, food intake and body weight 411–14
Phloretin, lithium transport in erythrocytes 503–6
Phobia
  clinical 160
  clinical diagnosis 181, 182
  definition 180
  diazepam treatment 184
  experimental 160, 161
Phobic-obsessive psychoneurosis
  multicenter trial and drugs 129–38
Pimozide 305
  conditional discrimination tests 315, 615–18
Pineal, gonadal effects 290
Piperazines and rat behaviour 245–54
Piribedil
  exploration and locomotor activity 248–51
  rat behaviour 245–54
Place preference paradigm 314
Polyelectromyography 493
Probenecid 532–4
Prolactin
  and fluphenazine behavioural effects 603–7
  and haloperidol 549–52
Prolactin response
  circadian values 75
  neuroleptics and fluphenazine 69–76
  psychiatric scales 74–6
Psychomotor skills, assessments 265
Psychopharmacology
  information exchange 201–3
  publications 198

Radioimmunoassay, melatonin in serum 297, 298, 523–6
Receptors
  antidepressant 295
Receptors, dopamine
  CNS, genetics 298
  neuroleptic 304, 543–7
  purification 294
  regulation 302
Receptors, opiate 4–6
  chronic haloperidol 549–52
  distribution 5, 17
Reinforcement, brain substrates 467–72
Reward system, endogenous 467, 468
Rheumatoid factor in affective disorders 92, 94
RO4-4602 570, 571

Schizoaffective disorders, lithium prophylaxis 507–10
Schizophrenia
  AMDP system 300, 301, 322, 323
  depot neuroleptic assessment 79–89
  dopamine receptors 301
  LSD binding 319
  prolactin response to neuroleptics 69–76
  readmission and depot neuroleptics 84–7
Scopolamine and aggression in mice 54, 55
Self-stimulation 468, 469
Senile dementia
  cerebral activators 448–50
  clinical pharmacology 447–53
  neuropeptides 452
  neurotransmitters 435–43, 450–52
  vasodilator drugs 447–50
Septo-hippocampal system 151, 153
Serotonin and alcohol tolerance 460–2
Serotonin axons, hippocampal 148
Sleep
  ischaemic episodes 101, 102, 104
  nocturnal angina 99–104
  stages 99, 103
Sodium lactate, electrophysiology of panic 511–14
Spiperidol, rat brain binding and phencyclidine 311
Spiperone, D2 receptor binding 545
Stress
  opiate catalepsy 281
  rat brain endorphins 287, 288, 595–8

Tachyphylaxis 14, 15
Tardive dyskinesia, methylphenidate 309, 491–4
Task complexity, pimozide 615–18
Temperature, morphine and rectal 363–71
Tetrahydroisoquinolines 343–51
  and aldehydes 345–8
  biochemistry 345, 346
  CNS effects 348–50
  nucleus 344
  sites of action 351
  synthesis 344, 345
Tolerance, behavioural and neural substrate 151
Trace amines, dopamine reaction and rat striatum 286, 287, 577–80
Trazodone, self-rating mood scale 519–22
Tricyclic antidepressants and aggression in mice 162
Tryptophan, seasonal variation in parturient women 287, 515–18
Tyramine, nigro-striatal 289

Vasopressin, DG- and alcohol tolerance 462, 463
Vigilance 190
WHO Collaborating Center Network on Psychopharmacology 201–3

Progress in Neuro-Psychopharmacology
An International Research and Review Journal

EDITORIAL ADVISORY BOARD

V. N. BAGADIA, Bombay
A. BARBEAU, Montreal
J. BRUINVELS, Rotterdam
J. R. BUENO, Rio de Janeiro
W. E. BUNNEY, Bethesda
G. D. BURROWS, Melbourne
M. CAMPBELL, New York
G. B. CASSANO, Pisa
T. N. CHASE, Bethesda
J. COLLARD, Liège
A. J. COPPEN, Epsom
J. T. COYLE, Baltimore
P. CUATRECASAS, Res. Triangle Park
E. CUENCA, Cadiz
H. C. B. DENBER, Louisville
W. L. DEWEY, Richmond
E. F. DOMINO, Ann Arbor
J. ENGEL, Goteborg
S. GARATTINI, Milano
F. GARCIN, Quebec
J. GAUTIER, Quebec
L. GESSA, Cagliari
C. GIURGEA, Brussels
S. C. GOLDBERG, Rockville
A. GOLDSTEIN, Palo Alto
F. K. GOODWIN, Bethesda
L. F. GRAM, Copenhagen
J. P. GREEN, New York
R. N. GROVE, Quebec
W. E. HAEFELY, Basle
H. HALBACH, Wildenwart
L. HARRIS, Richmond
R. HEACOCK, Ottawa
H. HEIMANN, Tubingen
P. D. HRDINA, Ottawa
T. HOKFELT, Stockholm
P. HUGHES, Geneva
M. R. ISSIDORIDES, Athens
T. M. ITIL, New York
H. ITOH, Tokyo
J. JACOB, Paris
W. JANKE, Dusseldorf
L. F. JARVIK, Los Angeles
L. JULOU, Paris
K. KALANT, Toronto
S. KANOWSKI, Berlin
N. KHAZAN, Baltimore
K. F. KILLAM, Davis
N. S. KLINE, Orangeburg
C. KORNETSKY, Boston
H. W. KOSTERLITZ, Aberdeen
F. LABRIE, Quebec
M. H. LADER, London
H. LAL, Kingston, RI
V. G. LONGO, Roma
P. LUNDBORG, Goteborg
L. MANARA, Milano
P. MANDEL, Strasbourg
W. R. MARTIN, Lexington
M. O. MAYKUT, Ottawa
N. K. MELLO, Belmont, MA
H. Y. MELTZER, Chicago
J. MENDELS, Philadelphia
J. MENDLEWICZ, Brussels
P. L. MORSELLI, Paris
R. D. MYERS, West Lafayette
R. A. NICOLL, San Francisco
M. O. OLATAWURA, Ibadan
A. OLIVERIO, Roma
R. PAOLETTI, Milano
C. B. PERT, Bethesda
P. PICHOT, Paris
A. PLETSCHER, Basle
S. N. PRADHAN, Washington
A. J. PRANGE, Chapel Hill
E. RICHELSON, Rochester
K. RICKELS, Philadelphia
L. N. ROBINS, St. Louis
I. ROOTMAN, Ottawa
R. H. ROTH, New Haven
B. SALETU, Vienna
N. SARTORIUS, Geneva
G. J. SARWER-FONER, Ottawa
M. SCHOU, Risskov
C. R. SCHUSTER, Chicago
W. J. SHOEMAKER, San Diego
B. SHOPSIN, New York
L. SHUSTER, Boston
E. J. SIMON, New York
P. SIMON, Paris
P. SINGH, Quebec
T. L. SOURKES, Montreal
C. N. STEFANIS, Athens
R. STRETCH, Ottawa
F. SULSER, Nashville
S. SZARA, Rockville
L. TERENIUS, Uppsala
T. THOMPSON, Minneapolis
M. TRABUCCHI, Milano
L. TRENHOLM, Ottawa
K. UNNA, Chicago
L. VALZELLI, Milano
W. L. VEALE, Calgary
A. VILLENEUVE, Quebec
O. VINAR, Prague
E. L. WAY, San Francisco
J. S. WERRY, Auckland
D. WHEATLEY, Twickenham
J. R. WITTENBORN, New Brunswick, NJ
J. WOODS, Ann Arbor

ORGANIZATION OF THE JOURNAL

The Journal contains four sections:

Critical reviews and theoretical articles

In this section are included minireview articles and theoretical papers supported by and giving immediate rise to clinical and experimental investigations. The critical reviews consist of clear, concise accounts of recent developments and some "hot" controversial problems. They are designed to give an overview to a large audience. The systematic publication of minireviews will be of great interest to researchers, teachers and advanced students enabling them to keep abreast of current scientific progress.

Full-length original papers

Papers in extenso reporting results on original research and technology in any field of basic and clinical neuro-psychopharmacology, will be presented in this section. Although high quality research articles are the first priority, the Editors wish to encourage technological papers related to the development of new methods, techniques and apparatus. Multidisciplinary studies providing direct correlation between basic, clinical and social data in the field of neuro-psychotropic drugs are welcomed.

Short papers for immediate publication

It is the policy of this journal to particularly encourage and facilitate the prompt publication of short papers.

- Notes and brief communications which for various pressing scientific reasons (priority in new hypotheses, preliminary innovative results, etc.) require rapid publication;

- Letters to the Editor, consisting of queries, scientific correspondence, etc.

News and intercommunications in neuro-psychopharmacology

This section has two main purposes. First, it is intended to provide NEWS, consisting of up-to-date information related to research, teaching and care delivery in the field of basic, clinical and social neuro-psychopharmacology. Secondly, this section will serve as a medium of unhampered *Intercommunications* among all the members of the neuro-psychopharmacological community. The Journal will publish regular announcements on: Past and forthcoming meetings; News from international and national organizations; Research news; Teaching and training programs; News on current and new drugs; Recent critical reviews, monographs and books; Book reviews, etc. In addition, Professional announcements (e.g. employment opportunities) will also be included.

- Special issues, or supplements devoted to comprehensive reviews and important topics discussed in recent meetings (conferences, symposiums, etc.) will periodically be published in the Journal.

N.B. For the preparation of manuscripts related to the above sections, please consult the INSTRUCTIONS TO CONTRIBUTORS.

CRITICAL REVIEWS AND THEORETICAL ARTICLES